In this episode of The BioHub Podcast by Avetix, Ben sits down with Dr. Arun Swaminathan, CEO of Coya Therapeutics, a clinical-stage biotechnology company developing therapies designed to enhance regulatory T cell function and target systemic inflammation and neuroinflammation.Arun brings more than 20 years of healthcare leadership experience across corporate strategy, business development, operations, and deal-making. At Coya, he is helping lead the company’s work in severe neurodegenerative diseases, including ALS, Alzheimer’s disease, frontotemporal dementia, and Parkinson’s disease, with a focus on immunomodulatory and Treg-based therapeutic approaches. In this conversation, we discuss the evolving treatment landscape in neurodegeneration, the role of neuroinflammation in CNS drug development, what it takes to build and finance a clinical-stage biotech, and how combination therapeutic strategies could shape the next generation of disease-modifying treatments.
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Episode 166 - Shawn Singh - CEO at Vistagen
Episode 165 - Karen Lewis - CPO of Cardurion Pharmaceuticals
Episode 164 - Natalia Misciattelli - CEO of AAVantgarde
Episode 163 - Ken Macnamara - CEO at Trogenix
Free AI-powered recaps of The BioHub - by Avetix and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.